Heise, "
Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers," Experimental and Clinical Endocrinology & Diabetes, vol.
both
insulin glulisine regimens (mean difference, -37 mg/dL vs.
Summary: Sanofi-aventis announced yesterday that the European Commission has approved APIDRAA (
insulin glulisine [rDNA origin] injection), a rapid-acting insulin analog for the control of hyperglycemia in adolescents and children (6 years and older) with diabetes.
The approval of Apidra (
insulin glulisine [rDNA origin] injection) for paediatric use provides children (6 years and older) with the option of using Apidra as part of their overall diabetes treatment plan, usually in combination with a basal insulin, it said.
A third insulin analog on the market,
insulin glulisine (Apidra), approved in 2004, has a pharmacokinetic profile that is similar to insulin aspart and lispro, but Mr.
Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of
insulin glulisine plus insulin glargine and oral antidiabetic drugs.
Insulin glulisine (Category C) has limited evidence of safe use in pregnancy.16 Recently published RC T comparing detemir with NPH insulin in TIDM in pregnancy has shown similar level of glycaemic control, hypoglycaemic episodes, and incidence of adverse perinatal outcomes in 2 arms and has not raised any safety issue with detemir.17 At present detemir is category B and glargine is category C drug for use in pregnancy.16 Glargine has safety concerns with regard to its increased mitogenic potency, compared to human insulin.
Rapid-acting insulin analogs include insulin aspart (NovoLog[R]), insulin lispro (Humalog[R]), and
insulin glulisine (Apidra[R]).
Insulin glulisine is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12).
A second study evaluated the administration of 1, 2, or 3 prandial injections of
insulin glulisine in patients whose A1C values were still above target following 14 weeks of insulin glargine optimization.